Role of urotensin-2 in 5-fluorouracil-related arterial vasoconstriction in cancer patients

Basit Öğe Kaydı
dc.contributor.authorŞeker, Mesut
dc.contributor.authorİsen, Hayati Can
dc.contributor.authorÇevirme, Nidal
dc.contributor.authorAydın, Sinem
dc.contributor.authorBilici, Ahmet
dc.contributor.authorBulut, Huri
dc.contributor.authorYasin, Ayşe İrem
dc.contributor.authorÇoban, Ezgi
dc.contributor.authorDemir, Tarık
dc.contributor.authorAliyev, Altay
dc.contributor.authorKoçyiğit, Abdurrahim
dc.contributor.authorTürk, Hacı Mehmet
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T20:02:14Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T20:02:14Z
dc.date.issued2018
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000444108500007
dc.descriptionPubMed ID: 30121640
dc.description.abstractBackground: The aim of this study was to identify the possible relationship of 5-fluorouracil (5-FU)-related arterial vasoconstriction with urotensin-2 (UT-2), which has a high potential as an endogenic vasoconstrictor. Methods: We assigned the patients to 1 of 3 groups. Patients in group 1 received a bolus of 5-FU, those in group2a continuous infusion (CI) of 5-FU, and those in group 3 no 5-FU, which was also a control group. Pre- and post-treatment UT-2 levels and brachial arterial diameters were measured and recorded in all patients. Results: 132 patients were included in the study. Pre-and post-treatment brachial artery diameters were similar in all groups: in group 1 (3.28 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.740), in group 2 (3.57 +/- 0.47 vs. 3.46 +/- 0.45 mm, p = 0.441) and in the control group (3.51 +/- 0.52 vs. 3.25 +/- 0.44 mm, p = 0.818). Pre-and post-treatment UT-2 levels were significantly different in each group: in group 1 (39.5 +/- 30.9 vs. 56.7 +/- 27.1 ng/ml, p = 0.0001), in group 2 (37.7 +/- 33.7 vs. 62.5 +/- 37.7 ng/ml, p = 0.0001) and in the control group (52.9 +/- 40.2 vs. 60.8 +/- 40.7 ng/ml, p = 0.006). Conclusion: Our findings suggest that UT-2 has a high potential as a vasoconstrictor agent in our bodies and its level increases through a bolus or CI 5-FU. Increased UT-2 levels are likely to play a role in 5-FU-related cardiac toxicity pathogenesis.
dc.identifier.citationŞeker, M., İsen, H. C., Çevirme, N., Aydın, S., Bilici, A., Bulut, H. ... Türk, H. M. (2018). Role of urotensin-2 in 5-fluorouracil-related arterial vasoconstriction in cancer patients. Journal of Oncology Research and Treatment, 41(9), 545-549. https://dx.doi.org/10.1159/000490120
dc.identifier.doi10.1159/000490120
dc.identifier.endpage549
dc.identifier.issn2296-5270
dc.identifier.issn2296-5262
dc.identifier.issue9
dc.identifier.scopusqualityQ3
dc.identifier.startpage545
dc.identifier.urihttps://dx.doi.org/10.1159/000490120
dc.identifier.urihttps://hdl.handle.net/20.500.12511/3589
dc.identifier.volume41
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherKarger
dc.relation.ispartofOncology Research and Treatmenten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subject5-Fluorouracil
dc.subjectCardiotoxicity
dc.subjectUrotensin 2
dc.subjectVasoconstriction
dc.titleRole of urotensin-2 in 5-fluorouracil-related arterial vasoconstriction in cancer patients
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Bilici, A..pdf
Boyut:
236.69 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu